Brocabe
Bruton’s tyrosine kinase inhibitor, oral antineoplastic. Indicated for the treatment of oncohematologic neoplasms (chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma), Waldenström’s macroglobulinemia, and graft-versus-host disease.
Therapeutic Area
Oncohematology
Active Ingredient
Ibrutinib
Line
Oncology
Dosage forms
140 mg x 90 hard capsules and 120 hard capsules
